New hope for rare GIST mutations: regorafenib tested as second-line therapy
NCT ID NCT06087263
First seen Jan 21, 2026 · Last updated Jun 06, 2026 · Updated 27 times
Summary
This early-phase study tests whether the drug regorafenib can help control gastrointestinal stromal tumors (GIST) that have specific genetic changes (KIT exon 17, 18, or 14 mutations, or SDHB deficiency) after imatinib has stopped working. Only 3 adults with measurable, unresectable tumors are enrolled. The main goal is to check safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.